• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Nevro Corp.

    4/12/24 4:51:38 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care
    Get the next $NVRO alert in real time by email
    DEFA14A 1 nvro-defa_14a-2024.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a)

    of the Securities Exchange Act of 1934

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material under §240.14a-12

    NEVRO CORP.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

    img128067818_0.jpg 

    Your Vote Counts! NEVRO CORP. 2024 Annual Meeting of Stockholders Vote by May 22, 2024 11:59 PM ET NEVRO CORP. 1800 BRIDGE PARKWAY REDWOOD CITY, CA 94065 V44218-P08796 You invested in NEVRO CORP. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held via the Internet on May 23, 2024 at 10:30 AM PDT at www.virtualshareholdermeeting.com/NVRO2024. Get informed before you vote This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet or by mail. You may view the Notice, Proxy Statement and Annual Report on Form 10-K online at www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by requesting prior to May 9, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* May 23, 2024 10:30 AM, PDT Virtually at: www.virtualshareholdermeeting.com/NVRO2024 *Please check the meeting materials for any special requirements for meeting attendance.

     


     

    img128067818_1.jpg 

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. We encourage you to access and review all of the important information contained in the proxy materials before voting. Board Recommends Voting Items 1. Election of directors to hold office until the 2025 annual meeting of stockholders or until their successors are elected. For Nominees: 01) D. Keith Grossman 02) Michael DeMane 03) Kevin Thornal 04) Kirt P. Karros 05) Sri Kosaraju 06) Shawn T McCormick 07) Kevin O’Boyle 08) Karen Prange 09) Susan Siegel 10) Elizabeth Weatherman 2. To ratify the selection, by the Audit Committee of the Company’s Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024 For 3. To approve, on a non-binding, advisory basis, the compensation of the named executive officers as disclosed in the Company’s proxy statement in accordance with the compensation disclosure rules of the Securities and Exchange Commission For NOTE: The proxies are authorized to vote in their discretion upon such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V44219-P08796

     


    Get the next $NVRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVRO

    DatePrice TargetRatingAnalyst
    2/10/2025$4.50 → $5.85Underperform → Hold
    Jefferies
    2/7/2025$6.00 → $5.85Neutral → Overweight
    Piper Sandler
    12/3/2024$5.00Equal Weight
    Wells Fargo
    12/2/2024$9.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    8/9/2024Sell → Neutral
    Citigroup
    8/8/2024Underperform → Peer Perform
    Wolfe Research
    8/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024Neutral → Underweight
    JP Morgan
    More analyst ratings

    $NVRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nevro upgraded by Jefferies with a new price target

    Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously

    2/10/25 7:02:54 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Nevro from Neutral to Overweight and set a new price target of $5.85 from $6.00 previously

    2/7/25 8:27:53 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Wells Fargo initiated coverage on Nevro with a new price target

    Wells Fargo initiated coverage of Nevro with a rating of Equal Weight and set a new price target of $5.00

    12/3/24 7:38:11 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NEVRO CORP (0001444380) (Issuer)

    4/3/25 4:30:33 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Director Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NEVRO CORP (0001444380) (Issuer)

    4/3/25 4:30:35 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Director Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NEVRO CORP (0001444380) (Issuer)

    4/3/25 4:30:38 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

    REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

    3/4/25 4:15:00 PM ET
    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

    Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

    AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

    2/6/25 9:30:21 AM ET
    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

    REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induceme

    1/21/25 4:30:00 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    SEC Filings

    View All

    SEC Form 15-12G filed by Nevro Corp.

    15-12G - NEVRO CORP (0001444380) (Filer)

    4/14/25 8:30:09 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Nevro Corp.

    EFFECT - NEVRO CORP (0001444380) (Filer)

    4/8/25 12:15:06 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.

    SCHEDULE 13D/A - NEVRO CORP (0001444380) (Subject)

    4/4/25 3:49:25 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Financials

    Live finance-specific insights

    View All

    Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

    REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

    3/4/25 4:15:00 PM ET
    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

    Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

    AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

    2/6/25 9:30:21 AM ET
    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro Reports Third-Quarter 2024 Financial Results

    Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma

    11/11/24 4:05:00 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nevro Corp.

    SC 13G - NEVRO CORP (0001444380) (Subject)

    12/4/24 4:27:18 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Nevro Corp.

    SC 13D/A - NEVRO CORP (0001444380) (Subject)

    11/14/24 5:31:36 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nevro Corp.

    SC 13G/A - NEVRO CORP (0001444380) (Subject)

    11/14/24 5:18:25 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Leadership Updates

    Live Leadership Updates

    View All

    Nevro Enters Into Cooperation Agreement With Engaged Capital

    Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi

    2/21/24 4:06:00 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro Appoints Jon R. Shear as Vice President, Corporate Development

    REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately.   "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and

    4/19/21 7:00:00 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications

    REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately.   "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a

    11/30/20 7:00:00 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care